These findings demonstrate that inhibition of TRPM2 reduces leukemia growth and increases cytotoxicity in myeloid leukemia through mitochondrial dysfunction, increased mitochondrial ROS production, reduced antioxidant response and bioenergetics, and significantly impaired autophagy. This evidence concerns the gene TRPM2 and myeloid leukemia.